BMGL
Basel Medical Group Ltd Ordinary SharesBMGL
BMGL
About: Basel Medical Group Ltd provides general and subspecialized orthopedic, trauma and sports medicine services such as knee/hip replacements, sports medicine/surgery, spine surgery, foot/ankle surgery and minimally invasive orthopedic procedures, as well as neurosurgical treatments. Key revenue is generated from Singapore.
–
Funds holding %
of 7,419 funds
–
Analysts bullish %
Fund manager confidence
Research analyst outlook
We haven’t received any recent analyst ratings for BMGL.
Financial journalist opinion
Neutral
GlobeNewsWire
1 week ago
Basel Medical Group Signs Agreement to Acquire Bethesda Medical to Strengthen Healthcare Ecosystem in Singapore and Southeast Asia
Singapore, April 11, 2025 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (Nasdaq: BMGL), today announced the signing of a definitive agreement by its subsidiary Basel Medical Group Pte. Ltd. to acquire Bethesda Medical Pte. Ltd., a leading Singapore-based healthcare provider specializing in diagnostic imaging and outpatient care. The agreement marks a significant step in Basel Medical Group's strategic expansion in Singapore and the broader Southeast Asian healthcare market. The completion of the acquisition is subject to customary closing conditions and is expected to take place on or around April 30, 2025 or such other date agreed by the parties.
Neutral
GlobeNewsWire
1 month ago
Basel Medical Group Ltd Announces Exercise of Overallotment Option
Singapore, March 19, 2025 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (the “Company”) (Nasdaq: BMGL), a Singapore-based clinical provider of general and subspecialized orthopedic and trauma services, sports medicine and surgery, orthopedic procedures, as well as neurosurgical treatments, today announced the full exercise of the overallotment option by the representative of the underwriters of its initial public offering to purchase an additional 330,750 ordinary shares at a price of US$4.00 per share and the closing of such issuance. The shares of the Company commenced trading on the Nasdaq Capital Market on February 25, 2025, under the ticker symbol “BMGL”.
Neutral
GlobeNewsWire
1 month ago
Basel Medical Group Ltd Announces Closing of US$8,820,000 Initial Public Offering
Singapore, March 03, 2025 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (the “Company”) (Nasdaq: BMGL), a Singapore-based clinical provider of general and subspecialized orthopedic and trauma services, sports medicine and surgery, orthopedic procedures, as well as neurosurgical treatments, today announced the closing of its initial public offering of 2,205,000 ordinary shares at a public offering price of US$4.00 per share. The shares commenced trading on the Nasdaq Capital Market on February 25, 2025, under the ticker symbol “BMGL”. The Company has registered for resale up to 2,000,000 existing ordinary shares by certain selling shareholders. The Company will not receive any proceeds from the sale of those shares by the selling shareholders.
Neutral
Seeking Alpha
1 month ago
U.S. IPO Weekly Recap: Small Asia-Based Names List, As TV Adtech MNTN And Others Join The Pipeline
Four IPOs and four SPACs listed this week. Four IPOs and two SPACs submitted initial filings. The March IPO market is set to start off with a quiet week.
Neutral
GlobeNewsWire
1 month ago
Basel Medical Group Ltd Prices US$8,820,000 Initial Public Offering
Singapore, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (the “Company”) (Nasdaq: BMGL), a Singapore-based clinical provider of general and subspecialized orthopedic and trauma services, sports medicine and surgery, orthopedic procedures, as well as neurosurgical treatments, today announced the pricing of its initial public offering of 2,205,000 ordinary shares at a public offering price of US$4.00 per share. The shares are expected to commence trading on the Nasdaq Capital Market on February 25, 2025, under the ticker symbol “BMGL”. Concurrently, the Company has registered for resale up to 2,000,000 existing ordinary shares by certain selling shareholders. The Company will not receive any proceeds from the sale of those shares by the selling shareholders.
Charts implemented using Lightweight Charts™